Bio News
Johnson & Johnson (J&J) has entered into an agreement with Sail Biomedicines that includes an option to acquire the company for $2.58 billion (about 3.87 trillion won). Through an upfront payment of $785 million (about 1.18 trillion won) and an equity investment, J&J secured in vivo CAR-T technology and the preclinical-stage SAIL-0839, which targets autoimmune diseases. The agreement puts J&J in the competition to acquire in vivo cell therapy companies, following Eli Lilly and BMS, and the company plans to expand the indications in the future.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
